Biosimilars
Polpharma and Wuesthoff succeed in revoking MS drug patent
The Opposition Division of the European Patent Office has revoked a Biogen patent, which covers treatment for multiple sclerosis. In May 2020, Polphar
...
1 July 2021 by Amy Sandys